Brought to you by 
AstraZeneca licenses CytoFab from Protherics for £195mm; terminated
19 May 2015
Executive Summary
Protherics PLC (inflammation and cancer) has licensed AstraZeneca worldwide rights to develop and commercialize its CytoFab candidate that has completed Phase II development for severe sepsis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca licenses CytoFab from Protherics for £195mm; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice